TSE:OGI Organigram (OGI) Stock Price, News & Analysis C$1.59 +0.01 (+0.63%) As of 05/2/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock About Organigram Stock (TSE:OGI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Organigram alerts:Sign Up Key Stats Today's RangeC$1.56▼C$1.6050-Day RangeC$1.27▼C$1.6752-Week RangeC$1.22▼C$2.87Volume34,808 shsAverage Volume221,854 shsMarket CapitalizationC$196.43 millionP/E RatioN/ADividend YieldN/APrice TargetC$3.67Consensus RatingBuy Company OverviewOrganigram Inc. is a Canadian licensed producer of cannabis products. Organigram focuses on producing exceptional, indoor-grown cannabis for patients and adult recreational consumers, as well as developing global business partnerships.Read More… Organigram Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreOGI MarketRank™: Organigram scored higher than 60% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingOrganigram has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageOrganigram has received no research coverage in the past 90 days.Read more about Organigram's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Organigram is -3.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Organigram is -3.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioOrganigram has a PEG Ratio of 0.42. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioOrganigram has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for OGI. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOrganigram does not currently pay a dividend.Dividend GrowthOrganigram does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for OGI. News and Social Media2.4 / 5News Sentiment0.34 News SentimentOrganigram has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Organigram this week, compared to 1 article on an average week.Search Interest4 people have searched for OGI on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Organigram insiders have not sold or bought any company stock.Percentage Held by Insiders31.32% of the stock of Organigram is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 8.37% of the stock of Organigram is held by institutions.Read more about Organigram's insider trading history. Receive OGI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Organigram and its competitors with MarketBeat's FREE daily newsletter. Email Address OGI Stock News HeadlinesOrganigram (TSE:OGI) Trading Up 3.2% - Here's What HappenedApril 30, 2025 | americanbankingnews.comAlliance Global Partners Sticks to Its Buy Rating for OrganiGram Holdings (OGI)April 12, 2025 | markets.businessinsider.comGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s already performing nearly twice as well as gold this year and looks ready to go much higher. If you wait for the news to hit, you’ll already be too late.May 4, 2025 | Golden Portfolio (Ad)Organigram Global Inc. (OGI)April 1, 2025 | finance.yahoo.comOrganigram announces official rebranding to Organigram GlobalMarch 27, 2025 | markets.businessinsider.comBritish American Tobacco buying at OrganiGram Holdings (OGI)March 6, 2025 | theglobeandmail.comOrganiGram Holdings Inc. (NASDAQ:OGI) Q1 2025 Earnings Call TranscriptFebruary 13, 2025 | msn.comOrganiGram Holdings Inc (OGI) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ...February 12, 2025 | finance.yahoo.comSee More Headlines OGI Stock Analysis - Frequently Asked Questions How have OGI shares performed this year? Organigram's stock was trading at C$2.30 at the beginning of 2025. Since then, OGI shares have decreased by 30.9% and is now trading at C$1.59. View the best growth stocks for 2025 here. How do I buy shares of Organigram? Shares of OGI stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Organigram own? Based on aggregate information from My MarketBeat watchlists, some other companies that Organigram investors own include Canopy Growth (CGC), Aurora Cannabis (ACB), Innovative Industrial Properties (IIPR), Aurora Cannabis (ACB), Canopy Growth (WEED), Aphria (APHA) and NVIDIA (NVDA). Industry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryCannabis Current SymbolTSE:OGI CIKN/A Webwww.organigram.ca Phone844-644-4726FaxN/AEmployees987Year FoundedN/APrice Target and Rating Average Stock Price TargetC$3.67 High Stock Price TargetC$4.35 Low Stock Price TargetC$3.15 Potential Upside/Downside+130.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)C($0.47) Trailing P/E RatioN/A Forward P/E Ratio9.74 P/E Growth0.42Net IncomeC$-57,230,259.02 Net Margins-31.69% Pretax MarginN/A Return on Equity-17.59% Return on Assets-5.56% Debt Debt-to-Equity Ratio3.07 Current Ratio3.36 Quick Ratio2.62 Sales & Book Value Annual SalesC$180.58 million Price / Sales1.09 Cash FlowC$0.41 per share Price / Cash Flow3.85 Book ValueC$2.85 per share Price / Book0.56Miscellaneous Outstanding Shares123,542,347Free FloatN/AMarket CapC$196.43 million OptionableNot Optionable Beta1.13 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free Report This page (TSE:OGI) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organigram Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organigram With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.